Nanoparticulate lipid adjuvants induce robust immunity against RSV infection
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Respiratory viral infections research · Animal Virus Infections Studies · Viral gastroenteritis research and epidemiology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (31)
Show source-provided references
1. Mazur NI, Caballero MT, Nunes MC. Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies. Lancet, 2024, 404: 1143–115610.1016/S0140-6736(24)01716-1 ↗
2. Gupta S, Pellett S. Recent developments in vaccine design: from live vaccines to recombinant toxin vaccines. Toxins, 2023, 15: 56310.3390/toxins15090563 ↗
3. Nguyen B, Tolia NH. Protein-based vaccine approaches for infectious diseases. NPJ Vaccines, 2020, 8: 89–10210.3390/vaccines8010089 ↗
4. Mohsen MO, Heath MD, Cabral-Miranda G, et al. Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. J Immunother Cancer, 2019, 7: 114–12610.1186/s40425-019-0587-z ↗
5. Moyer TJ, Kato Y, Abraham W, et al. Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nat Med, 2020, 26: 430–44010.1038/s41591-020-0753-3 ↗
6. Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med, 2023, 388: 595–60810.1056/NEJMoa2209604 ↗
7. Wan J, Wang C, Wang Z, et al. CXCL13 promotes broad immune responses induced by circular RNA vaccines. Proc Natl Acad Sci USA, 2024, 121: e240643412110.1073/pnas.2406434121 ↗
8. Romerio A, Gotri N, Franco AR, et al. New glucosamine-based TLR4 agonists: design, synthesis, mechanism of action, and in vivo activity as vaccine adjuvants. J Med Chem, 2023, 66: 3010–302910.1021/acs.jmedchem.2c01998 ↗
9. Didierlaurent AM, Laupèze B, Di Pasquale A, et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines, 2017, 16: 55–6310.1080/14760584.2016.1213632 ↗
10. Bonam SR, Partidos CD, Halmuthur SKM, et al. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci, 2017, 38: 771–79310.1016/j.tips.2017.06.002 ↗
11. Ke G, Su D, Li Y, et al. An accurate, high-speed, portable bifunctional electrical detector for COVID-19. Sci China Mater, 2021, 64: 739–74710.1007/s40843-020-1577-y ↗
12. Leroux-Roels G, De Boever F, Maes C, et al. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. Vaccine, 2019, 37: 2694–270310.1016/j.vaccine.2019.04.011 ↗
13. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov, 2021, 20: 817–83810.1038/s41573-021-00283-5 ↗
14. Arora R, Katiyar SS, Kushwah V, et al. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study. Expert Opin Drug Deliver, 2017, 14: 165–17710.1080/17425247.2017.1264386 ↗
15. Swaminathan G, Thoryk EA, Cox KS, et al. A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens. Vaccine, 2016, 34: 110–11910.1016/j.vaccine.2015.10.132 ↗
16. Miao L, Li L, Huang Y, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol, 2019, 37: 1174–118510.1038/s41587-019-0247-3 ↗
17. Anindita J, Tanaka H, Yamakawa T, et al. The effect of cholesterol content on the adjuvant activity of nucleic-acid-free lipid nanoparticles. Pharmaceutics, 2024, 16: 181–19510.3390/pharmaceutics16020181 ↗
18. Alameh MG, Tombácz I, Bettini E, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity, 2021, 54: 2877–2892.e710.1016/j.immuni.2021.11.001 ↗
19. Kawai A, Noda M, Hirata H, et al. Lipid nanoparticle with 1,2-Di-O-octadecenyl-3-trimethylammonium-propane as a component lipid confers potent responses of Th1 cells and antibody against vaccine antigen. ACS Nano, 2024, 18: 16589–1660910.1021/acsnano.4c00278 ↗
20. He Z, Le Z, Shi Y, et al. A multidimensional approach to modulating ionizable lipids for high-performing and organ-selective mRNA delivery. Angew Chem Int Ed, 2023, 62: e20231040110.1002/anie.202310401 ↗
21. Sehlinger A, Dannecker PK, Kreye O, et al. Diversely substituted polyamides: macromolecular design using the Ugi four-component reaction. Macromolecules, 2014, 47: 2774–278310.1021/ma500504w ↗
22. McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science, 2013, 340: 1113–111710.1126/science.1234914 ↗
23. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science, 2013, 342: 592–59810.1126/science.1243283 ↗
24. Madhi SA, Polack FP, Piedra PA, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med, 2020, 383: 426–43910.1056/NEJMoa1908380 ↗
25. Glaxo Smith Kline. AS01e Saponin Adjuvant Vaccine Compositions. US Patent, 10,143,745 B2, 2018
26. Wu XB, Shi JX, Ou YM, et al. Sequential enantioselective Ugi-4CR/post-Ugi transformation strategy: a precise construction of structurally diverse azaspiro polycyclic scaffolds. Sci China Chem, 2024, 67: 576–58610.1007/s11426-023-1782-9 ↗
27. Nazeri MT, Farhid H, Mohammadian R, et al. Cyclic imines in Ugi and Ugi-type reactions. ACS Comb Sci, 2020, 22: 361–40010.1021/acscombsci.0c00046 ↗
28. Soni D, Borriello F, Scott DA, et al. From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation. Sci Adv, 2024, 10: 374710.1126/sciadv.adg3747 ↗
29. Kayamuro H, Abe Y, Yoshioka Y, et al. The use of a mutant TNF-α as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials, 2009, 30: 5869–587610.1016/j.biomaterials.2009.07.009 ↗
30. Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol, 2019, 14: 1084–108710.1038/s41565-019-0591-y ↗
31. Forster III J, Nandi D, Kulkarni A. mRNA-carrying lipid nanoparticles that induce lysosomal rupture activate NLRP3 inflammasome and reduce mRNA transfection efficiency. BioMater Sci, 2022, 10: 5566–558210.1039/D2BM00883A ↗